Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 9Prostatic Neoplasms 6Hematopoietic and Lymphatic System Neoplasm 6Hematologic Neoplasms 6Colorectal Neoplasms 5Breast Neoplasms 5Anatomic Stage I Breast Cancer AJCC v8 5Pancreatic Neoplasms 3Neoplasms 3Malignant Solid Neoplasm 3Leukemia, Myeloid, Acute 3Urinary Bladder Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Mouth Neoplasms 2Melanoma 2Head and Neck Carcinoma 2Glioma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2COVID-19 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Tonsillar Neoplasms 1

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bilateral Breast Carcinoma × Practice Guidelines as Topic × 90 days × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡